ro5137382
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT01507168)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Glypican-3INHIBITOR
GPC3 inhibitor
- Ganglioside GD3OTHER
Ganglioside GD3 other
Interacts with CD16/Fc gamma RIIIa and triggers antibody-dependent cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109429 ↗
Also known as
- rg-7686
- ro5137382
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01507168 | Phase 2 | Feb 1, 2012 | Roche |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1